Assembly Biosciences (ASMB) EBIAT (2016 - 2025)
Assembly Biosciences (ASMB) has 11 years of EBIAT data on record, last reported at -$9.2 million in Q3 2025.
- For Q3 2025, EBIAT rose 4.34% year-over-year to -$9.2 million; the TTM value through Sep 2025 reached -$38.5 million, up 5.53%, while the annual FY2024 figure was -$40.2 million, 34.38% up from the prior year.
- EBIAT reached -$9.2 million in Q3 2025 per ASMB's latest filing, up from -$10.2 million in the prior quarter.
- Across five years, EBIAT topped out at -$8.8 million in Q1 2025 and bottomed at -$60.3 million in Q4 2021.
- Average EBIAT over 5 years is -$18.6 million, with a median of -$16.9 million recorded in 2023.
- Peak YoY movement for EBIAT: plummeted 461.45% in 2021, then soared 62.83% in 2022.
- A 5-year view of EBIAT shows it stood at -$60.3 million in 2021, then skyrocketed by 62.83% to -$22.4 million in 2022, then skyrocketed by 51.05% to -$11.0 million in 2023, then rose by 5.72% to -$10.3 million in 2024, then grew by 11.02% to -$9.2 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$9.2 million in Q3 2025, -$10.2 million in Q2 2025, and -$8.8 million in Q1 2025.